{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:15:42Z","timestamp":1793121342644,"version":"4.5.0"},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Vestibular migraine has no established treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To test the efficacy of rizatriptan for treating vestibular migraine attacks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This double-blind, randomized clinical trial of rizatriptan vs placebo was conducted from December 2014 through July 2020 (data analyses in 2021 and sensitivity analyses in 2022 and 2024) at 2 tertiary neurotologic centers. Adults with vestibular migraine were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>All participants underwent prospective observation to confirm diagnosis and illness activity and were then randomized in a 2:1 ratio to receive rizatriptan 10 mg or placebo to treat up to 3 vestibular migraine attacks per participant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Participants rated symptoms as absent, mild, moderate, or severe at scheduled intervals. Primary outcomes were the percentage of attacks with reductions in vertigo and unsteadiness\/dizziness from moderate or severe to absent or mild at 1 hour. Secondary outcomes were the percentage of attacks with complete resolution of vestibular symptoms at 1 hour; reductions in headache and associated symptoms at 1 hour; use of rescue medications after 1 hour; reductions in vestibular, headache, and associated symptoms at 24 hours without rescue medications; treatment satisfaction and quality of life at 48 hours; and rates of serious adverse effects and discontinuation due to adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 222 total participants (mean [SD] age, 42.3 [11.7] years; 70.7% were women), 134 (60.4%) with active illness treated 307 attacks. Efficacy was tested using 240 attacks with vestibular symptoms rated as moderate or severe when participants took study drug. At 1 hour, rizatriptan did not differ from placebo for reducing vertigo (73\/151 [48.3%] vs 50\/88 [56.8%] attacks; odds ratio [OR], 0.71 [95% CI, 0.42-1.21]), unsteadiness\/dizziness (29\/151 [19.2%] vs 11\/89 [12.4%] attacks; OR, 1.69 [95% CI, 0.80-3.57]), or any secondary outcomes. Similar percentages of participants in rizatriptan and placebo groups (26.4% for both groups) added rescue remedies after 1 hour. At 24 hours, rizatriptan had medium effects over placebo for unsteadiness\/dizziness (OR, 2.65) and motion sensitivity (OR, 3.58). Post hoc analyses of all treated attacks found a medium effect favoring rizatriptan for headache and photophobia or phonophobia at 24 hours. Treatment satisfaction was equivocal. Quality of life was mixed. No participants experienced serious adverse effects or discontinued treatment for adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this study, rizatriptan was ineffective at 1 hour for treating vestibular migraine attacks and had limited benefit on symptoms at 24 hours. Findings do not support using rizatriptan for vestibular migraine attacks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02447991\">NCT02447991<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.1006","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:01:40Z","timestamp":1747047700000},"page":"676","source":"Crossref","is-referenced-by-count":16,"title":["Rizatriptan vs Placebo for Attacks of Vestibular Migraine"],"prefix":"10.1001","volume":"82","author":[{"given":"Jeffrey P.","family":"Staab","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Otorhinolaryngology\u2013Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D. Z.","family":"Eggers","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Jen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"LeMahieu","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Geske","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghu","family":"Liu","sequence":"additional","affiliation":[{"name":"Section of Public Health and Community Dentistry, School of Dentistry, University of California, Los Angeles"},{"name":"Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, California"},{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna R.","family":"Hofschulte","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Roxana","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Neff","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2013Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil T.","family":"Shepard","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2013Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin L.","family":"McCaslin","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Baloh","sequence":"additional","affiliation":[{"name":"Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi250022r1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/VES-2012-0453","article-title":"Vestibular migraine: diagnostic criteria.","volume":"22","author":"Lempert","year":"2012","journal-title":"J Vestib Res"},{"issue":"9","key":"noi250022r3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The International Classification of Headache Disorders, 3rd edition (beta version).","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","journal-title":"Cephalalgia"},{"issue":"1","key":"noi250022r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition.","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"issue":"1","key":"noi250022r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/VES-201644","article-title":"Vestibular migraine: diagnostic criteria.","volume":"32","author":"Lempert","year":"2022","journal-title":"J Vestib Res"},{"issue":"1-2","key":"noi250022r6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/VES-2009-0343","article-title":"Classification of vestibular symptoms: towards an international classification of vestibular disorders.","volume":"19","author":"Bisdorff","year":"2009","journal-title":"J Vestib Res"},{"issue":"6","key":"noi250022r7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1212\/01.wnl.0000237539.09942.06","article-title":"Migrainous vertigo: prevalence and impact on quality of life.","volume":"67","author":"Neuhauser","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"noi250022r8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/MAO.0000000000001900","article-title":"The epidemiology of vestibular migraine: a population-based survey study.","volume":"39","author":"Formeister","year":"2018","journal-title":"Otol Neurotol"},{"issue":"1","key":"noi250022r9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1055\/s-0039-3402735","article-title":"Vestibular migraine I: mechanisms, diagnosis, and clinical features.","volume":"40","author":"Baloh","year":"2020","journal-title":"Semin Neurol"},{"issue":"1","key":"noi250022r10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/0333102419869317","article-title":"Vestibular migraine: an update on current understanding and future directions.","volume":"40","author":"Huang","year":"2020","journal-title":"Cephalalgia"},{"issue":"3","key":"noi250022r11","first-page":"350","article-title":"Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness.","volume":"18","author":"Bikhazi","year":"1997","journal-title":"Am J Otol"},{"issue":"3","key":"noi250022r12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/00129492-200205000-00024","article-title":"Migraine-associated dizziness: patient characteristics and management options.","volume":"23","author":"Reploeg","year":"2002","journal-title":"Otol Neurotol"},{"issue":"3","key":"noi250022r13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00415-009-0111-3","article-title":"\u201cVestibular migraine\u201d: effects of prophylactic therapy with various drugs: a retrospective study.","volume":"256","author":"Baier","year":"2009","journal-title":"J Neurol"},{"issue":"2","key":"noi250022r14","first-page":"103","article-title":"Treatment of migraine related vertigo with lamotrigine an observational study.","volume":"2","author":"Bisdorff","year":"2004","journal-title":"Bull Soc Sci Med Grand Duche Luxemb"},{"issue":"1","key":"noi250022r15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1196\/annals.1325.057","article-title":"Use of topiramate (topamax) in a subgroup of migraine-vertigo patients with auditory symptoms.","volume":"1039","author":"Carmona","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"559","key":"noi250022r16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/03655230701596491","article-title":"Migraine-associated vertigo: clinical characteristics of Japanese patients and effect of lomerizine, a calcium channel antagonist.","author":"Iwasaki","year":"2007","journal-title":"Acta Otolaryngol Suppl"},{"issue":"11","key":"noi250022r17","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s00405-013-2786-4","article-title":"Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.","volume":"271","author":"Lepcha","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"noi250022r18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/2193-1801-3-231","article-title":"Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study.","volume":"3","author":"Taghdiri","year":"2014","journal-title":"Springerplus"},{"issue":"1","key":"noi250022r19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MAO.0000000000000596","article-title":"Vestibular migraine in an otolaryngology clinic: prevalence, associated symptoms, and prophylactic medication effectiveness.","volume":"36","author":"Van Ombergen","year":"2015","journal-title":"Otol Neurotol"},{"issue":"10","key":"noi250022r20","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s10072-015-2270-6","article-title":"Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study.","volume":"36","author":"Teggi","year":"2015","journal-title":"Neurol Sci"},{"issue":"10","key":"noi250022r21","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1007\/s00405-015-3874-4","article-title":"Acetazolamide in vestibular migraine prophylaxis: a retrospective study.","volume":"273","author":"\u00c7elebisoy","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"noi250022r22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/lary.25445","article-title":"Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial.","volume":"126","author":"Salviz","year":"2016","journal-title":"Laryngoscope"},{"issue":"10","key":"noi250022r23","first-page":"805","article-title":"[Flunarizine in the prophylaxis of vestibular migraine:a randomized controlled trial].","volume":"30","author":"Yuan","year":"2016","journal-title":"Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"issue":"4","key":"noi250022r24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bjorl.2016.04.022","article-title":"Prophylactic treatment of vestibular migraine.","volume":"83","author":"Salmito","year":"2017","journal-title":"Braz J Otorhinolaryngol"},{"key":"noi250022r25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fneur.2017.00524","article-title":"The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine.","volume":"8","author":"Liu","year":"2017","journal-title":"Front Neurol"},{"issue":"1","key":"noi250022r26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5152\/iao.2019.6522","article-title":"The effectiveness of medical prophylactic treatment on vestibular migraine and its effect on the quality of life.","volume":"16","author":"\u00c7elik","year":"2020","journal-title":"J Int Adv Otol"},{"issue":"1","key":"noi250022r27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s13063-019-3903-5","article-title":"Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG).","volume":"20","author":"Bayer","year":"2019","journal-title":"Trials"},{"issue":"9","key":"noi250022r28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40263-023-01037-0","article-title":"Network meta-analysis of different treatments for vestibular migraine.","volume":"37","author":"Chen","year":"2023","journal-title":"CNS Drugs"},{"issue":"9","key":"noi250022r29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1017\/S0022215122001979","article-title":"A systematic review and meta-analysis of prophylactic medication of vestibular migraine.","volume":"137","author":"Yiannakis","year":"2023","journal-title":"J Laryngol Otol"},{"key":"noi250022r30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.799002","article-title":"New anti-CGRP medications in the treatment of vestibular migraine.","volume":"12","author":"Hoskin","year":"2022","journal-title":"Front Neurol"},{"issue":"9","key":"noi250022r31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3390\/medicina59091560","article-title":"Monoclonal antibodies targeting CGRP: a novel treatment in vestibular migraine.","volume":"59","author":"Lovato","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"noi250022r32","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231161809","article-title":"Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: a prospective observational cohort study.","volume":"43","author":"Russo","year":"2023","journal-title":"Cephalalgia"},{"key":"noi250022r33","doi-asserted-by":"publisher","DOI":"10.1177\/01455613231202200","article-title":"Evaluation of vestibular functions in a case of vestibular migraine with successful treatment with erenumab.","volume":"1-5","author":"Inui","year":"2023","journal-title":"Ear Nose Throat J"},{"issue":"10","key":"noi250022r34","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/head.14835","article-title":"A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: the INVESTMENT study.","volume":"64","author":"Sharon","year":"2024","journal-title":"Headache"},{"key":"noi250022r35","doi-asserted-by":"publisher","first-page":"A114","DOI":"10.1186\/1129-2377-16-S1-A114","article-title":"P074. Almotriptan in the acute treatment of vestibular migraine: a retrospective study.","volume":"16","author":"Cassano","year":"2015","journal-title":"J Headache Pain"},{"issue":"3","key":"noi250022r36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10194-008-0035-9","article-title":"Headaches related to triptans therapy in patients of migrainous vertigo.","volume":"9","author":"Prakash","year":"2008","journal-title":"J Headache Pain"},{"issue":"4","key":"noi250022r37","article-title":"Pharmacological interventions for prophylaxis of vestibular migraine.","volume":"2023","author":"Webster","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"noi250022r38","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1212\/01.WNL.0000049476.40047.A3","article-title":"Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial.","volume":"60","author":"Neuhauser","year":"2003","journal-title":"Neurology"},{"issue":"7","key":"noi250022r39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice.","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"issue":"1","key":"noi250022r41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0090-9556(24)15007-6","article-title":"Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.","volume":"28","author":"Vyas","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"noi250022r42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411417901","article-title":"Guidelines for controlled trials of drugs in migraine: third edition: a guide for investigators.","volume":"32","author":"Tfelt-Hansen","year":"2012","journal-title":"Cephalalgia"},{"key":"noi250022r44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease.","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"noi250022r45","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"issue":"3","key":"noi250022r46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1212\/WNL.51.3.773","article-title":"A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks.","volume":"51","author":"Kramer","year":"1998","journal-title":"Neurology"},{"issue":"5","key":"noi250022r47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1468-2982.1999.019005525.x","article-title":"Efficacy and safety of rizatriptan wafer for the acute treatment of migraine: Rizatriptan Wafer Protocol 049 Study Group.","volume":"19","author":"Ahrens","year":"1999","journal-title":"Cephalalgia"},{"issue":"4","key":"noi250022r48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/bimj.201800107","article-title":"Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products.","volume":"61","author":"Rahlfs","year":"2019","journal-title":"Biom J"},{"key":"noi250022r49","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1526-4610.2008.01335.x","article-title":"Ten years of rizatriptan: from development to clinical science and future directions.","volume":"49","author":"Hargreaves","year":"2009","journal-title":"Headache"},{"issue":"4","key":"noi250022r51","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2307\/2531743","article-title":"Power calculations for matched case-control studies.","volume":"44","author":"Dupont","year":"1988","journal-title":"Biometrics"},{"key":"noi250022r2","unstructured":"International Classification of Vestibular Disorders (ICVD). Accessed January 27, 2024. https:\/\/jvr-web.org\/icvd"},{"key":"noi250022r40","unstructured":"Maxalt (rizatriptan benzoate) tablets, package insert. Whitehouse Station. February 2007. Accessed January 27, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020864s013lbl.pdf"},{"key":"noi250022r43","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. National Institutes of Health, National Cancer Institute; 2010. Accessed January 27, 2024. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html"},{"key":"noi250022r50","unstructured":"Hintze? J. Power Analysis and Sample Size 11 (PASS Users\u2019 Guide). Statistical Analysis and Graphics (NCSS), LLC, 2011. Accessed August 7, 2022. http:\/\/www.ncss.com?"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2833458\/jamaneurology_staab_2025_oi_250022_1751558099.30635.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:00:30Z","timestamp":1752505230000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2833458"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.1006","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}